We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
- Authors
Bramhall, S R; Rosemurgy, A; Brown, P D; Bowry, C; Buckels, J A; Marimastat Pancreatic Cancer Study Group
- Abstract
The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer performed to date, compares marimastat, the first of a new class of agents, with gemcitabine.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Vol 19, Issue 15, p3447
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2001.19.15.3447